Today Soligenix was granted a patent to produce a topical agent to treatment for treatment in pediatric Crohn’s disease. It should be noted that pediatric Crohn’s is a little different than Crohn’s in adults due to the different issues that are faced with younger patients (height, health, weight). The drug works with beclomethasone dipropionate which works in the upper and lower gastrointestinal tract. The drug has been used since the 1970s and Soligenix is trying to develop an oral form of the medication. The company will start trials that should be started this year on SGX203 (oral form). Hopefully another future drug that can be used in the drug arsenal against Crohn’s!